RIGEL PHARMACEUTICALS INC director Alison L. Hannah received an equity award in the form of Restricted Stock Units. The filing shows a grant of 5,750 shares of Common Stock at a price of $0.00 per share, reflecting a compensation-related award rather than a market purchase.
These shares are to be acquired upon vesting of the Restricted Stock Unit award. According to the terms, the units will fully vest on the date prior to the company’s next Annual Meeting, as long as she continues to serve on the Board of Directors. After this grant, her direct Common Stock holdings reported in this filing total 16,375 shares.
Rigel Pharmaceuticals director Mark W. Frohlich was granted 5,750 restricted stock units of common stock at no cost. These units will be acquired upon vesting and are scheduled to fully vest on the date prior to the company’s next annual meeting, subject to his continued service on the board. Following this equity award, Frohlich beneficially owns 7,000 shares of Rigel’s common stock.
Ali-Jackson Kamil reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Kamil Ali-Jackson received a stock grant tied to board service. The Form 4 shows an award of 5,750 shares of Common Stock at no cash cost, delivered as Restricted Stock Units. These units will fully vest on the date prior to the company’s next Annual Meeting, as long as the director continues serving on the Board. After this grant, the director holds 15,125 shares of Common Stock directly.
Rigel Pharmaceuticals reports that Armistice Capital, LLC and Steven Boyd jointly hold 1,280,000 shares of Common Stock, representing 6.93% of the class as of 03/31/2026. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement, and the Master Fund is the direct holder. The statement is a Schedule 13G joint filing signed on 05/15/2026.
Rigel Pharmaceuticals has entered into an exclusive, royalty-bearing worldwide license agreement with Arvinas entities and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant) and related products. VEPPANU is approved in the United States for certain ER+, HER2‑negative, ESR1‑mutated advanced or metastatic breast cancer.
Rigel will pay an upfront $70 million, up to $15 million tied to transition activities, and up to $320 million in potential regulatory and sales milestone payments, plus tiered royalties from the mid‑teens to mid‑twenties on net sales. Rigel will lead global development and commercialization, while reimbursing specified ongoing development costs up to $40 million. The agreement becomes effective after expiration or termination of the applicable Hart‑Scott‑Rodino antitrust waiting period.
Rigel Pharmaceuticals, Inc. ownership disclosure: Soleus Capital Master Fund, L.P. and affiliated entities report beneficial ownership of 968,108 shares of Rigel common stock, representing 5.2% of the class. The percentage is calculated using 18,502,080 shares outstanding as of April 30, 2026 per Rigel's Form 10-Q cover.
The filing attributes the shares to the Master Fund and describes the ownership/management chain (Soleus Capital, LLC; Soleus Capital Group, LLC; Soleus Capital Management, L.P.; Soleus GP, LLC) and a disclaimer of beneficial ownership by related entities, signed by Guy Levy.
Rigel Pharmaceuticals reported first quarter 2026 total revenues of $58.8 million, driven by $54.9 million in net product sales and $3.9 million in contract revenues from collaborations. Net product sales rose 26% year over year, reflecting growth across its hematology-oncology portfolio.
TAVALISSE net product sales were $37.3 million, up 31%, GAVRETO reached $9.6 million, up 7%, and REZLIDHIA generated $8.0 million, up 31% versus the same period in 2025. Rigel posted net income of $8.7 million, or $0.47 basic and $0.44 diluted per share, compared with $11.4 million a year earlier, as total costs and expenses increased to $46.9 million on higher R&D and commercial spending.
Cash, cash equivalents and short-term investments were $146.7 million as of March 31, 2026. The company reaffirmed its 2026 outlook for total revenues of approximately $275–$290 million, including net product sales of $255–$265 million and contract revenues of $20–$25 million, and continues to anticipate positive full-year net income while funding ongoing clinical programs such as R289.
Rigel Pharmaceuticals reported a profitable first quarter of 2026 with higher product sales and continued investment in its pipeline. Total revenues were $58.8 million, up from $53.3 million a year earlier, driven by net product sales of $54.9 million. TAVALISSE, REZLIDHIA and GAVRETO net sales were $37.3 million, $8.0 million and $9.6 million, respectively, each growing versus 2025.
Net income was $8.7 million compared with $11.4 million, as operating expenses and a higher $3.0 million tax provision offset revenue gains. Diluted EPS was $0.44. Cash, cash equivalents and short‑term investments totaled $146.7 million, with $45.0 million of term debt outstanding at March 31, 2026 and operating cash flow of $2.7 million.
Rigel highlighted progress in its R289 Phase 1b study and broader olutasidenib collaborations in hematologic cancers and high‑grade glioma. The company received notice in April 2026 that Eli Lilly will terminate their global RIPK1 collaboration effective June 15, 2026, after which Rigel expects to regain full rights to the compounds. In May 2026 Rigel refinanced its term loan into a new $40.0 million revolving credit facility with MidCap.
Rigel Pharmaceuticals reports that Eli Lilly and Company has elected to terminate their License and Collaboration Agreement covering ocadusertib (previously R552) and other RIPK1 inhibitors. Lilly’s termination is in its entirety and becomes effective June 15, 2026.
The agreement, signed on February 18, 2021, had granted Lilly an exclusive worldwide license to develop and commercialize RIPK1 inhibitors for non-CNS and CNS diseases, with potential milestone payments and royalties to Rigel. After termination, Lilly’s rights to the licensed compounds will cease, subject to transition provisions, and Rigel expects to regain full rights to these programs.
Rigel is evaluating the impact of the termination and, following this step and the earlier end of the CNS disease program effective in November 2025, does not expect to receive future milestones or royalties under the agreement.
Rigel Pharmaceuticals, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 14, 2026. Stockholders will elect three directors to serve until the 2029 annual meeting, approve amendments to its equity incentive and employee stock purchase plans, cast an advisory vote on executive pay, and ratify Ernst & Young LLP as independent auditor for 2026.
The equity proposals would add 500,000 shares to the 2018 Equity Incentive Plan and 360,000 shares to the 2000 Employee Stock Purchase Plan. As of March 19, 2026, there were 18,480,019 shares of common stock outstanding and entitled to vote. The board unanimously recommends voting “FOR” all five proposals.